BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress
October 07, 2016 at 09:14 AM EDT
* Seattle Genetics and Agensys, an affiliate of Astellas, highlight promising enfortumab vedotin (ASG-22ME) and ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress Source text for Eikon: Further company coverage:
